Pharmaceuticals, Biotechnology and Life Sciences
Basilea Pharmaceutica’s analysis of the registrational phase 2 study of potential of derazantinib in the treatment of FGFR-driven tumors, also confirmed the safety profile and tolerability of the drug candidate observed in previous clinical studies.
Cellular Biomedicine Group (CBMG) will begin picking the patients to test anti-BCMA CAR-T therapy targeting relapsed and refractory Multiple Myeloma in China.
Vast Therapeutics has a drug candidate, BIOC51, which is active against Bacillus anthracis, commonly known as anthrax, it said found out in an in vitro study carried out at Lovelace Biomedical.
Protagonist Therapeutics has injected mimetic peptide (PTG-300) into patients with beta thalassemia, to test it in a study to make it a treatment for this rare disease.
Amgen and UCB on Tuesday reported getting licence to market Evenity to treat patients with osteoporosis, who have high risk…
Omya has developed Omyasprint, an orally disintegrating tablet (ODT) based on the excipient Omyapharm and vitamin B 12.
Oncology focused pharmaceutical company Corvus Pharmaceuticals has started enrolling patients in the second arm of its ongoing Phase 1/1b dose-escalation study to test combination of CPI-006, a humanized monoclonal antibody directed against CD73, with CPI-444, a selective and potent inhibitor of the adenosine A2A receptor.
Regen BioPharma’s researches have combined its lead NR2F6 small molecule agonist with Cannabidiol (CBD) to provide a dynamic therapy for treating inflammatory bowel disease (IBD), and it could work.
Lupin got the EC approval of NaMuscla for reducing myotonia symptoms in adult patients, and has partnering discussions ongoing for commercialization of NaMuscla in European territories outside Germany and the UK.
Royal College of Surgeons in Ireland team of researchers (RCSI) said Tuesday they have developed a new treatment for tuberculosis (TB), a potential practical treatment to be scaled-up and mass-produced for clinical testing.